Report of Foreign Issuer (6-k)
May 05 2016 - 2:01PM
Edgar (US Regulatory)
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For period ending 05 May 2016
GlaxoSmithKline plc
(Name of registrant)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F
Form 20-F x Form 40-F
--
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
Yes No x
--
GlaxoSmithKline plc
Result of AGM
GlaxoSmithKline plc ('GSK') announces that at its Annual General Meeting ('AGM') today, all resolutions were passed by shareholders. The full text of each resolution is contained in the 2016 Notice of AGM, which is available on the GSK website,
www.gsk.com
.
GSK AGM Poll Results
The following table shows the total number of votes cast for each resolution:
Resolution
|
Total votes for
*
|
%
|
Total votes against
|
%
|
Total votes cast
|
Votes withheld
**
|
1
|
To receive the 2015 Annual Report
|
3,669,218,924
|
99.05
|
35,061,988
|
0.95
|
3,704,280,912
|
5,261,084
|
2
|
Approval of the Annual Remuneration Report
|
2,540,987,583
|
84.66
|
460,527,692
|
15.34
|
3,001,515,275
|
708,024,810
|
3
|
Election of Vindi Banga
|
3,685,603,989
|
99.46
|
20,087,621
|
0.54
|
3,705,691,610
|
3,847,903
|
4
|
Election of Dr Jesse Goodman
|
3,700,820,176
|
99.86
|
5,098,265
|
0.14
|
3,705,918,441
|
3,621,220
|
5
|
Re-election of Sir Philip Hampton
|
3,678,982,107
|
99.28
|
26,862,132
|
0.72
|
3,705,844,239
|
3,698,027
|
6
|
Re-election of Sir Andrew Witty
|
3,683,792,948
|
99.40
|
22,182,401
|
0.60
|
3,705,975,349
|
3,569,171
|
7
|
Re-election of Professor Sir Roy Anderson
|
3,613,878,165
|
97.52
|
92,011,809
|
2.48
|
3,705,889,974
|
3,648,285
|
8
|
Re-election of Stacey Cartwright
|
3,614,959,774
|
97.55
|
90,964,624
|
2.45
|
3,705,924,398
|
3,615,316
|
9
|
Re-election of Simon Dingemans
|
3,546,542,373
|
95.70
|
159,260,080
|
4.30
|
3,705,802,453
|
3,739,812
|
10
|
Re-election of Lynn Elsenhans
|
3,689,867,659
|
99.57
|
16,065,159
|
0.43
|
3,705,932,818
|
3,606,897
|
11
|
Re-election of Judy Lewent
|
3,603,842,229
|
97.24
|
102,181,719
|
2.76
|
3,706,023,948
|
3,513,813
|
12
|
Re-election of Urs Rohner
|
3,592,628,299
|
96.95
|
113,209,089
|
3.05
|
3,705,837,388
|
3,695,508
|
13
|
Re-election of Dr Moncef Slaoui
|
3,600,056,654
|
97.14
|
105,875,118
|
2.86
|
3,705,931,772
|
3,611,731
|
14
|
Re-appointment of auditors
|
3,641,870,505
|
98.24
|
65,155,953
|
1.76
|
3,707,026,458
|
2,515,807
|
15
|
Remuneration of auditors
|
3,693,883,936
|
99.68
|
12,020,539
|
0.32
|
3,705,904,475
|
3,632,301
|
16
|
Authority for the company to make donations to political organisations and incur political expenditure
|
3,614,540,404
|
98.19
|
66,705,675
|
1.81
|
3,681,246,079
|
28,294,561
|
17
|
Authority to allot shares
|
3,557,940,858
|
96.09
|
144,791,595
|
3.91
|
3,702,732,453
|
6,808,690
|
18
|
Disapplication of pre-emption rights
***
|
3,206,747,187
|
88.23
|
427,795,940
|
11.77
|
3,634,543,127
|
74,993,676
|
19
|
Authority for the company to purchase its own shares
***
|
3,591,814,300
|
96.93
|
113,781,713
|
3.07
|
3,705,596,013
|
3,952,127
|
20
|
Exemption from statement of senior statutory auditor's name
|
3,648,560,466
|
99.15
|
31,169,134
|
0.85
|
3,679,729,600
|
29,811,350
|
21
|
Authorise reduced notice of a general meeting other than an AGM
***
|
3,223,721,215
|
87.61
|
455,747,014
|
12.39
|
3,679,468,229
|
30,073,919
|
Notes:
*
|
Includes discretionary votes.
|
**
|
A vote withheld is not a vote in law and is not counted in the calculation of the proportion of votes "For" or "Against" a resolution.
|
***
|
Indicates Special Resolutions requiring a 75% majority.
|
The Board notes the votes against and withheld in respect of resolution 2, the approval of the Remuneration Report. The Remuneration Committee will be conducting a review of the Directors' Remuneration Policy during 2016 and will consult and engage with major investors in advance of the vote on the Company's Remuneration Policy Report at our 2017 AGM.
Dr Stephanie Burns, Sir Deryck Maughan, Dr Daniel Podolsky and Hans Wijers did not stand for re-election as Directors, and stepped down from the Board with effect from the conclusion of the AGM.
In accordance with section 430(2B) of the Companies Act 2006, GSK confirms that Dr Stephanie Burns, Sir Deryck Maughan, Dr Daniel Podolsky and Hans Wijers will receive payment of fees for service whilst a Director but no other remuneration payment or payment for loss of office will be made in connection with their departure.
The following table provides further relevant information:
|
GSK's Sixteenth
AGM
(2016)
|
GSK's
Fifteenth AGM
(2015)
|
Issued share capital (excluding Treasury Shares)
|
4,871,555,095
|
4,866,216,110
|
Total votes cast and votes withheld lodged as a % of GSK's issued share capital (excluding Treasury Shares)
|
76.15%
|
75.30%
|
Total shareholder population
|
132,895
|
137,658
|
Total number of proxies lodged
|
8,020
|
8,686
|
% of shareholders who lodged proxies
|
6.03%
|
6.31%
|
Number of shareholders, corporate representatives and proxies who attended the AGM
|
448
|
403
|
V A Whyte
Company Secretary
5 May 2016
These results will shortly be available on the company's website at
www.gsk.com
.
GSK enquiries:
|
|
|
|
UK Media enquiries:
|
David Mawdsley
|
+44 (0) 20 8047 5502
|
(London)
|
|
Simon Steel
|
+44 (0) 20 8047 5502
|
(London)
|
|
Eleanor Craven
|
+44 (0) 20 8047 5502
|
(London)
|
|
Anna Carruth
|
+44 (0) 20 8047 5502
|
(London)
|
|
|
|
|
US Media enquiries:
|
Sarah Alspach
|
+1 202 715 1048
|
(Washington, DC)
|
|
Sarah Spencer
|
+1 215 751 3335
|
(Philadelphia)
|
|
Jenni Ligday
|
+1 202 715 1049
|
(Washington, DC)
|
|
|
|
|
Analyst/Investor enquiries:
|
Ziba Shamsi
|
+44 (0) 20 8047 5543
|
(London)
|
|
Tom Curry
|
+ 1 215 751 5419
|
(Philadelphia)
|
|
Gary Davies
|
+44 (0) 20 8047 5503
|
(London)
|
|
James Dodwell
|
+44 (0) 20 8047 2406
|
(London)
|
|
Jeff McLaughlin
|
+1 215 751 7002
|
(Philadelphia)
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
GlaxoSmithKline plc
(Registrant)
Date: May 05, 2016
By: VICTORIA WHYTE
----------------------
Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc
GSK (NYSE:GSK)
Historical Stock Chart
From Apr 2024 to May 2024
GSK (NYSE:GSK)
Historical Stock Chart
From May 2023 to May 2024